CMV reactivation and disease progression in response to different GVHD prophylaxis methods
July 25th 2023The difference in utilizing cytomegalovirus reactivation outcomes while on posttransplantation cyclophosphamide vs other graft-vs-hose disease agents has led to a better understanding in long-term disease and reinfection rates.
Factors Affecting Tacrolimus Concentrations in Children with β-Thalassemia Major receiving HSCT
November 15th 2021ASTCT recently published an article in their journal Nucleus detailing the impact of genotype and voriconazole co-administration on tacrolimus trough concentration in pediatric β-thalassemia major patients following allogeneic hematopoietic stem cell transplantation.